Arcosa, Inc., together with its subsidiaries, provides infrastructure-related products and solutions for the construction, engineered structures, and transportation markets in the United States. The company operates through three segments: Construction Products, Engineered Structures, and Transportation Products. The Construction Products segment offers natural and recycled aggregates; specialty materials; and construction site support equipment, including trench shields and shoring products for residential and non-residential construction, and specialty and other products, as well as for infrastructure construction. The Engineered Structures segment offers utility structures, wind towers, traffic and lighting structures, and telecommunication structures for electricity transmission and distribution, wind power generation, highway road construction, and wireless communication markets. This segment also sells its products to contractors and distributors serving state Departments of Transportation and state and municipality agencies. The Transportation Products segment offers inland barges, fiberglass barge covers, winches, marine hardware, and other transportation and industrial equipment to the commercial marine transportation companies, lessors, and industrial shippers. Arcosa, Inc. was incorporated in 2018 and is headquartered in Dallas, Texas.
Country
Sector
Themes
Also in
Price· split & dividend adjusted
No price history for this asset yet.
News & notes movingACA
Energy Transition & Power Demand▲
CRH to Acquire Arcosa for $8.5 Billion
CRH plc plans to acquire Arcosa, Inc. for approximately $8.5 billion, with closing expected in the first quarter of 2027. The deal would add about 35 million tons of annual aggregates production, lifting CRH's annualized U.S. aggregates production to more than 265 million tons and expanding its presence in 13 of the 50 largest U.S. metropolitan areas. Arcosa's Engineered Structures business, which holds a top-three market position, would also extend CRH into energy infrastructure tied to grid modernization, electrification and data center construction. CRH expects approximately $175 million of annual run-rate cost synergies by year three and says the transaction will be accretive to earnings, margin and cash flow in the first 12 months after completion. Financing includes a $5.8 billion bridge facility later reduced to $3.3 billion after a $2.5 billion term loan, with net debt at $15.4 billion as of June 30, 2026, and a pro forma net debt-to-adjusted EBITDA ratio of 2.4.
CRH Posts Q2 Earnings Beat but Housing Weakness and Costs Keep Risk-Reward Balanced
CRH reported second-quarter adjusted earnings of $2.21 per share, beating the Zacks Consensus Estimate of $1.96 by 12.8% and rising 14% year over year, while revenues grew 6% to $10.78 billion. The company reaffirmed 2026 adjusted EBITDA guidance of $8.1 billion to $8.5 billion and earnings guidance of $5.60 to $6.05 per share, supported by infrastructure demand that represents 40% of its fiscal 2025 end-market exposure. However, Americas Building Solutions revenues declined 2% to $2.12 billion and adjusted EBITDA fell 8% to $462 million, pressured by subdued U.S. new-build housing, cost inflation, and divestitures. Net debt rose to $15.4 billion as of June 30, 2026, from $14.2 billion at year-end 2025, and the company paused share buybacks after announcing the Arcosa acquisition. CRH carries a Zacks Rank #3 (Hold), with a forward price-to-earnings ratio of 15.32 that is below its sub-industry average of 18.41 but above its five-year median of 14.58.
Arcosa misses Q2 estimates and suspends financial outlook
Arcosa reported second-quarter results that fell short of analyst expectations and suspended its practice of providing financial guidance due to its pending merger with CRH. Non-GAAP earnings per share came in at $1.13, missing estimates by $0.05, while revenue of $658.7 million, a 1.7% increase year-over-year, missed by $27.4 million. Operating cash flow from continuing operations was negative $24.7 million, compared to positive $38.0 million in the prior-year period, and free cash flow was negative $51.0 million, down from $16.8 million a year ago. Capital expenditures rose to $58.8 million, reflecting increased investment in core growth platforms. The company ended the quarter with $432.1 million in cash and no borrowings on its $700 million revolving credit facility, and net debt to adjusted EBITDA stood at 1.9 times.
Arcosa reported second-quarter earnings of $1.13 per share, missing the Zacks Consensus Estimate of $1.18 per share and down from $1.27 per share a year ago. Revenue came in at $658.7 million, below the consensus estimate of $687.4 million and down from $736.9 million in the prior-year quarter. The earnings surprise was negative 4.24%, while the revenue miss was 4.17%. The company has beaten consensus EPS estimates in three of the last four quarters. Arcosa shares have gained about 36.6% year to date, outperforming the S&P 500's 13% advance.
CRH reported second quarter 2026 financial results with total revenues of $10.8 billion, a 6% increase over the prior year, driven by positive pricing momentum, favorable underlying demand, and contributions from acquisitions. Net income rose 13% to $1.5 billion, while Adjusted EBITDA grew 7% to $2.6 billion, with both net income margin and Adjusted EBITDA margin expanding. The company invested $1.4 billion in 17 acquisitions year-to-date and announced an $8.5 billion agreement to acquire Arcosa, reinforcing its position as a leading aggregates and critical infrastructure player in North America. CRH reaffirmed its full-year 2026 guidance for Net income of $3.9 billion to $4.1 billion, Adjusted EBITDA of $8.1 billion to $8.5 billion, and Diluted EPS of $5.60 to $6.05. The company also declared a quarterly dividend of $0.39 per share, a 5% increase, and completed $0.7 billion in share buybacks year-to-date, though it paused new buyback tranches pending the Arcosa acquisition.
Halper Sadeh LLC, an investor rights law firm, is investigating whether the proposed acquisitions of Arcosa, Bio-Techne, Iridium Communications, and LCI Industries are fair to shareholders. The firm is examining Arcosa's sale to CRH for $150.00 per share, Bio-Techne's sale to Merck KGaA for $73.00 per share in cash, Iridium's sale to Rocket Lab for $27.00 in cash plus Rocket Lab shares, and LCI Industries' sale to Patrick Industries for 1.2440 shares of Patrick common stock per LCI share. Halper Sadeh may seek increased consideration or additional disclosures on behalf of shareholders, and encourages them to contact the firm at no cost to discuss their legal rights and options.
Brodsky & Smith Investigating LCI Industries, Iridium, Bio-Techne, and Arcosa Mergers
Brodsky & Smith is investigating the boards of LCI Industries, Iridium Communications, Bio-Techne Corporation, and Arcosa over potential fiduciary duty breaches in their respective merger agreements. LCI is being acquired by Patrick Industries in an all-stock deal where LCI shareholders would receive 1.2440 Patrick shares per LCI share. Iridium is being acquired by Rocket Lab for $54 per share in cash and stock, with an enterprise value of approximately $8.0 billion. Bio-Techne is being acquired by Merck KGaA for $73.00 per share in cash, representing a total enterprise value of approximately $11.3 billion. Arcosa is being acquired by CRH for $150.00 per share in cash, with a total enterprise value of approximately $8.5 billion. The investigations focus on whether the boards failed to conduct a fair process and whether shareholders are receiving fair value.
CRH to Acquire Arcosa for $8.5 Billion Following Leadership Changes
CRH has agreed to acquire U.S.-based Arcosa for $8.5 billion, a record deal for the company that significantly expands its North American infrastructure and aggregates presence. The acquisition follows recent management changes, including the appointment of Aylwyn Bryan as CFO effective May 12, 2026, and Danilo Juvane as Head of Investor Relations effective May 26, 2026. CEO Jim Mintern stated the deal reinforces CRH's position as the number one infrastructure player in North America, capitalizing on robust demand for energy and utility infrastructure. Jefferies raised its price target on CRH to $165.50 from $149, maintaining a Buy rating, and estimates the acquisition will boost earnings per share by 5 to 6 percent from 2027.
CRH to acquire Arcosa for $8.5 billion in its largest deal ever
CRH has agreed to acquire US-based Arcosa for $8.5 billion in cash, marking the largest acquisition in the company's history. The deal significantly expands CRH's presence in North American infrastructure and aggregates markets. CRH shares have risen 28.4% over the past year, 116.5% over three years, and 143.1% over five years, with the stock recently trading at $113.05. The acquisition is expected to shift CRH's earnings exposure toward US infrastructure, energy, and utility-related demand, while integration and funding of the all-cash transaction will be key factors to monitor.
Brodsky & Smith investigates Arcosa, Fathom, Nuvalent, and Dana boards over merger deals
Brodsky & Smith is investigating the boards of Arcosa, Fathom Holdings, Nuvalent, and Dana Incorporated over potential fiduciary duty breaches in their respective merger agreements. Arcosa is being acquired by CRH for $150.00 per share in cash, with a total enterprise value of approximately $8.5 billion. Fathom Holdings is being acquired by Bed Bath & Beyond in a deal implying an equity value of about $53.38 million, with an exchange ratio of 0.2236 Bed Bath & Beyond shares per Fathom share. Nuvalent is being acquired by GSK for $124.00 per share in cash in a deal valued at $10.6 billion. Dana is being acquired by Eaton Corporation in a transaction valued at approximately $5.1 billion, where Eaton shareholders will own at least 50.1% and Dana shareholders approximately 49.9% of the combined company, and Eaton will receive a cash distribution of about $1.1 billion.
Apogee Therapeutics surges 50% on AbbVie acquisition, Getty Images jumps 150% on OpenAI deal
Several stocks made significant premarket moves on Monday. Apogee Therapeutics soared 50% after AbbVie confirmed it will acquire the biotechnology company in a $10.9 billion all-cash transaction at $135.11 per share, a 49% premium to Thursday's close. Arcosa rose more than 7% after CRH announced an $8.5 billion all-cash acquisition valuing Arcosa at $150 per share, a 10% premium. SpaceX fell more than 5% in premarket trading, on pace for its sixth straight decline, though shares remain up 30% from its IPO price of $135. Getty Images surged 150% after announcing an agreement to integrate its content into OpenAI's search and ChatGPT. Alphabet fell nearly 2% after senior research scientist John Jumper left Google DeepMind for Anthropic, days after engineering VP Noam Shazeer joined OpenAI. Credo Technology rose more than 3% after Evercore ISI initiated coverage with an outperform rating, citing its evolution from a copper-related AI connectivity play to an optical one. Micron Technology gained 4.5% following price target hikes from Bernstein to $1,300 and Needham to $1,550, leading memory peers Seagate Technology, Western Digital, and Sandisk as the top S&P 500 premarket performers.